Evaluating Modes of Influenza Transmission Between Humans
Evaluating Modes of Influenza Transmission Using a Human Challenge/Exposure Model
研究概览
研究类型
阶段
- 不适用
联系人和位置
学习地点
-
-
-
London、英国、NW1 0NH
- Retroscreen Virology Ltd
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18 to 45 years, inclusive.
- Comprehension of the study requirements; availability for the required study period, ability to attend scheduled study visits, and willingness to participate in the inpatient challenge.
- Willingness to provide written consent for participation after reading the Subject Information Sheet and Informed Consent Form and after having adequate opportunity to discuss the study with an Investigator or qualified deputy.
- H3N2 antibody titre levels recorded as < 1:10
- Good general health status as determined by a screening evaluation no greater than 160 days prior to the quarantine challenge phase.
- Subjects shall be registered with a general practitioner who will confirm a subjects' past medical history and their suitability to participate based on this. Consent will be obtained to receive this information.
- For female subjects, provision of a history of reliable contraceptive practices [hysterectomy or bilateral tubal ligation, oral or implanted contraceptive use, intrauterine device, barrier method plus spermicide, history of a single male partner with vasectomy and documentary evidence confirming sterility (negative sperm counts at the recommended post-operative intervals) or a history of abstinence deemed credible by the Investigator]. The provision of this history does NOT replace the requirement to perform, and obtain negative results in, pregnancy tests.
Exclusion Criteria:
- Presence of any significant acute or chronic, uncontrolled medical or psychiatric illness, including but not exclusive to the conditions listed in Appendix 7, that in the view of the Investigator is associated with increased risk of complications of respiratory viral illness [subjects with uncomplicated chronic diagnoses stable and treated for 3 months (e.g. mild hypertension well-controlled with medication may be enrolled) provided the condition and its therapy are not known to be associated with an immunocompromised state or increased risk of complications of respiratory viral illness].
- Health care workers (including doctors, nurses, medical students and allied healthcare professionals) anticipated to have patient contact within two weeks of viral challenge. Healthcare workers who volunteer should not work with patients until 14 days after challenge or until their symptoms are fully resolved (whichever is the longer). Health care workers who work in units housing severely immunocompromised patients (e.g. bone marrow transplant units) will be excluded from the study.
- Venous access deemed inadequate for the phlebotomy demands of the study.
- Positive serologic tests for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
- Evidence of drug abuse or a positive urine Class A drug or alcohol screen.
- Female subjects, who are known to be pregnant or who have a positive urine pregnancy test prior to challenge.
- Acute (within 7 days of challenge/exposure) or chronic use of any medication or other product (prescription or over-the-counter), for symptoms of rhinitis or nasal congestion or for any nasopharyngeal complaint, or use of any intranasal medication for any indication (this includes any corticosteroid or beta agonist containing nasal spray).
- Any history during adulthood of asthma, chronic obstructive pulmonary disease or any other condition requiring bronchodilator therapy. A history of childhood asthma until and including the age of 12 is acceptable.
- Smokers unwilling/unable to desist for the quarantine phase duration of the study and any smoker who has a >10 pack year history of smoking. A nicotine test will be done at study specific screening and must be negative prior to admission to the quarantine unit.
- Subjects who have type I or type II Diabetes Mellitus.
- Body Mass Index > 30.
- An Abnormal ECG deemed clinically relevant by the Investigator.
- Any anatomic or neurologic abnormality impairing the gag reflex or conducive to aspiration, or history suggestive of such a problem or any abnormality significantly altering the anatomy of the nose or nasopharynx.
- Receipt of systemic glucocorticoids (in a dose 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within six months prior to challenge.
- Receipt of any investigational drug within 6 months prior to challenge, or prior participation in a clinical trial of any Influenza vaccine, or any investigational vaccine or experimental Influenza viral challenge delivered directly to the respiratory tract within 1 year prior to challenge.
- History of adverse reaction to neuraminidase inhibitors e.g. oseltamivir
Presence of any febrile illness or symptoms of upper viral respiratory infection:
i. On the day of challenge/exposure or between admission for Influenza challenge/exposure and administration of the challenge inoculums (Donors) or exposure event (Recipients). Such subjects may be re-evaluated for enrollment in later studies after resolution of the illness; ii. Within 2 weeks prior to challenge or if challenge is set to occur during November, December, January, February, or March if there are any symptoms suggestive of viral respiratory infection occurring between screening and challenge.
- History of epistaxis (nose bleeds) more than 1 episode a month.
- Presence of household member or close contact (for an additional two weeks after discharge from the isolation facility) who is: (a) less than 3 years of age; (b) any person with any known immunodeficiency; (c) any person receiving immunosuppressant medications; (d) any person undergoing or soon to undergo cancer chemotherapy within 28 days of challenge; (e) any person who has diagnosed emphysema or COPD, is elderly residing in a nursing home, or with severe lung disease or medical condition including but not exclusive to the conditions listed in Appendix 4; or (f) any person who has received a transplant (bone marrow or solid organ).
- Any laboratory test which is abnormal and which is deemed by the Investigator to be clinically significant. (This includes blood chemistry, haematology, cardiac iso-enzymes, or urinalysis).
- Known IgA deficiency, immotile cilia syndrome, or Kartagener's syndrome.
- History of seasonal hay fever or a seasonal allergic rhinitis (SAR), including the use of symptomatic prescription only medication and non prescription medication.
- As a result of the medical interview, physical exam, or screening investigations, the Investigator considers the subject unfit for the study.
- Those employed or immediate relatives of those employed at Retroscreen Virology Ltd or the study site.
- Staff and students working directly in or for any of the Units in which the principal or a co-Investigator works.
- Immediate relatives of any of the principal or co-Investigators.
- Receipt of a northern hemisphere seasonal influenza vaccine in the 2006/07/08 winter seasons.
- Receipt of any systemic cytotoxic chemotherapy agent at any time.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
无干预:1个
|
|
|
实验性的:2
No face touch
|
|
|
实验性的:3
Surgical face mask
|
|
|
实验性的:4
Surgical face mask + no face touch
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
One or more individuals who develop a symptomatic illness confirmed as influenza A
大体时间:24 hourly
|
24 hourly
|
合作者和调查者
调查人员
- 首席研究员:Jonathan Van-Tam, MD、University of Nottingham
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.